Direct-acting antiretrovirals in genotype 1 HCV patients with mental health conditions safe, well tolerated

Direct-acting antiretrovirals in genotype 1 HCV patients with mental health conditions safe, well tolerated
Publish date: November 18, 2016
By: Whitney McKnight Frontline Medical News

BOSTON – Direct-acting antiretroviral therapies are safe and well tolerated in hepatitis C virus patients with comorbid psychiatric conditions, a study showed.

The finding that sustained virologic response (SVR) rates at 1 year were similar in genotype 1 HCV patients with and without psychiatric comorbidities could help end the stigma against treating this patient subgroup, stemming from when treatment with interferon risked psychiatric decompensation. That’s according to nurse practitioner Anne Moore, winner of this year’s Poster of Distinction Award at the American Association for the Study of Liver Diseases

Continue reading..